PINK:LOBEF

Lobe Sciences Stock News

Healthcare > Drug Manufacturers - Specialty & Generic

Buy LOBEF

*Your capital is at risk

$0.0889

+0.0166 (+22.96%)

At Close: Jun 03, 2026

Lobe Sciences updates investors on its regulatory and clinical development plans for its novel synthetic psilocin analogues L-130 and L-131

11:32am, Thursday, 07'th Jul 2022

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has announced the development of its initial Phase 1 study plan to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity

Lobe Sciences Ltd. to Participate in the Lytham Partners Spring 2022 Investor Conference

08:09am, Wednesday, 30'th Mar 2022

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announced today that it will be participating in the Lytham Par

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by